Recordati stock

REC · Borsa Italiana · EUR

€52.85Change from previous close: +0.38%Absolute change: +€0.20

Close · November 16, 2026

Price history

+1.15% over the period

1 year: from €52.25 (November 17, 2025) to €52.85 (November 16, 2026), +1.15%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€52.85
October 30, 2026€53.00
September 30, 2026€52.65
August 31, 2026€52.55
July 31, 2026€51.65
June 30, 2026€51.30
May 29, 2026€51.50
April 30, 2026€49.64
March 31, 2026€49.04
February 27, 2026€48.42
January 30, 2026€46.34
December 30, 2025€48.54
November 28, 2025€50.90
November 17, 2025€52.25

At a glance

  • The company

    Researches, develops, produces and sells pharmaceutical products for specialty care, primary care and rare diseases across multiple markets

  • Latest results

    Quarter to September 30, 2026 · EPS €0.66 (estimate €0.79)

TickerLandia's take on Recordati

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€43.76
52-wk high€53.80

−1.77% from the 52-week high

Analysts · 7 analysts

Average target€56.35+6.62% vs. price

Buy 1 · Hold 5 · Sell 1 · Hold

TickerLandia Fingerprint: Recordati

Compared with similar companies: very low risk.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Recordati is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Recordati's P/E today is 24.9, in line with the median of its last 10 fiscal years (25.7; between 20.3 and 30.6 from 2016 to 2025). Recordati's P/E (trailing 12 months): 21.0, in line with the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Recordati's metrics compared with similar companies
MetricRecordatiPosition in the groupBand
P/E (trailing 12 months)21.0Middle
Forward P/E13.9Middle
Operating margin32.6%Middle
ROE24.6%Middle
Debt/equity0.94Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Recordati. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€692.92M

Latest quarter · Q3 2026

Net income

€137.43M

Latest quarter · Q3 2026

Quarterly net margin

19.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€10.96B
P/E
21.0
EPS
€2.51
Volume
516.94K
Daily trading
€31.12M
Dividend yield
2.54%
Last ex-dividend on May 18, 2026

How Recordati is changing

All results
  • Revenue grew 12.6% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 124% of net income

  • Revenue has grown for 5 fiscal years in a row

Returns

Recordati returns with dividends

€1,000 invested in Recordati 5 years ago, on November 16, 2021, would be worth €1,058 today with dividends reinvested: +5.79% in total, +1.13% per year. On price alone it would be €932 (−6.79%).

PeriodRecordatiFTSE MIB€1,000 becomes
1 month−0.19%+3.60%€998
6 months+2.62%+5.58%€1,026
Year to date+8.88%+15.38%€1,089
1 year+3.85%+18.49%€1,039
3 years+28.07%+77.25%€1,281
5 years+5.79%+86.51%€1,058
10 years+167.10%+213.16%€2,671

Over the last 6 months it has done better than 20% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment

The chart in detail

Recordati: technical analysis

Recordati is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 13.3% below its all-time closing high (€60.95, February 13, 2025).

Trend
Upward
RSI (14 sessions)
49
Between 30 and 70
vs 200-session average
+4.08%

Support and resistance

Price areas where Recordati has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€53.35+0.95%7 touches, last on November 6, 2026
  2. Last price€52.85
  3. Support€52.60−0.47%7 touches, last on October 28, 2026
  4. Support€51.39−2.76%13 touches, last on September 7, 2026
  5. Support€50.49−4.46%6 touches, last on June 18, 2026

Volatility and risk

Over the last year it has moved little with the FTSE MIB.

Beta (1 year) vs FTSE MIB
0.16
Volatility (60 sessions, annualised)
7.7%
Largest fall in the last year
−14.87%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Recordati: seasonality

Average monthly price change over 37 years

+3.3%Jan+3.1%Feb+1.7%Mar+2.5%Apr+2.6%May−0.1%Jun+1.3%Jul−0.7%Aug−1.8%Sep+1.9%Oct+2.2%Nov−0.7%Dec

Over the last 37 years, the strongest month for Recordati has been January: +3.27% on average, positive in 22 years out of 36. The weakest has been September: −1.77% on average, positive in 15 years out of 37. November, the current month, has been positive in 19 years out of 36 (+2.20% on average).

Show chart data
MonthAverageMedianPositive years
January+3.27%+3.00%22 of 36
February+3.06%+1.43%24 of 37
March+1.67%+1.05%20 of 37
April+2.54%+1.22%23 of 37
May+2.60%+1.83%25 of 37
June−0.12%−0.53%16 of 37
July+1.28%+0.68%22 of 37
August−0.69%−0.64%16 of 37
September−1.77%−1.99%15 of 37
October+1.85%+2.33%23 of 37
November+2.20%+0.69%19 of 36
December−0.69%−0.66%17 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Recordati and its competitors

With revenue of EUR 2.6 billion in the fiscal year ended 31 December 2025, the group researches, develops, produces and sells pharmaceuticals through two business areas, Specialty and Primary Care and Rare Diseases. Its portfolio includes treatments for rare conditions such as maple syrup urine disease, Cushing's syndrome and cystinosis, with Carbaglu, Cystadrops and Isturisa, alongside cardiovascular and urology products such as Zanidip and Urorec, and oncology products including Eligard and Fotivda.

Headquarters
Milan, Italy
Employees
4,700
Founded
1926
Chief executive
Robert Koremans
Recordati and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
RecordatiREC$12.11B32.6%21.0+2.62%
OrionORNAV$15.93B38.1%22.0+52.14%
GrifolsGRF$8.76B18.9%16.4+28.19%
VirbacVIRP$3.28B15.8%19.1+2.00%
BayerBAYN$61.37B16.5%—+51.26%
GSKGSK$101.36B30.5%17.9+3.57%

Same industry or related industries, similar size. Compare Recordati with its competitors · Full profile